The role of Clusterin in cerebral amyloid angiopathy
Clusterin 在脑淀粉样血管病中的作用
基本信息
- 批准号:9147489
- 负责人:
- 金额:$ 34.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-30 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:APP-PS1Abeta clearanceAdultAffectAffinityAge-MonthsAllelesAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidAmyloid beta-ProteinAmyloidosisApolipoprotein EApolipoproteinsAstrocytesBehaviorBindingBiochemistryBiological AssayBiologyBlood VesselsBlood capillariesBlood flowBrainBreedingCell Culture TechniquesCerebral Amyloid AngiopathyCerebrovascular systemCerebrumCessation of lifeClinicCodeDataDementiaDepositionDrainage procedureElectrophysiology (science)ExtravasationGenesGeneticGenotypeGlial Fibrillary Acidic ProteinHemorrhageHippocampus (Brain)HistopathologyHumanIn VitroIndividualInflammationIntercellular FluidKnockout MiceLDL-Receptor Related Protein 1LDL-Receptor Related Protein 2LeadMeasuresMediatingMetabolismMicrodialysisMolecularMusMutationNeurofibrillary TanglesNeuronsPathologyPathway interactionsPatientsPharmacologyPopulationProteinsPublishingRoleSenile PlaquesSmooth Muscle MyocytesStagingStrokeTestingTherapeuticToxic effectTransgenic MiceVariantVascular DiseasesViralabeta depositionamyloid pathologyastrogliosisbrain parenchymabrain tissuecapillarycerebrovascularextracellulargenetic risk factorgenetic variantgenome wide association studyhuman datahuman tissuein vivomalignant breast neoplasmmouse modelnew therapeutic targetnovelnovel therapeuticsoverexpressionplexinpublic health relevancereceptorsulfated glycoprotein 2targeted treatmenttau Proteins
项目摘要
DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common cause of dementia and is characterized by extracellular plaques formed by the deposition of amyloid-β (Aβ) peptide and intracellular tangles comprised of hyperphosphorylated forms of the tau protein. Another common pathology in AD is cerebral amyloid angiopathy (CAA), caused by Aβ deposition in the walls of cerebral vessels leading to vascular dysfunction and hemorrhage. The strongest genetic risk factor for both AD and CAA is ε4 allele of the apolipoprotein E (APOE) gene, but multiple recent genome-wide association studies have proven that a similar apolipoprotein, Clusterin (CLU), also confers risk for AD. The role of CLU in CAA is unknown, but we have strong evidence that CLU is critically involved in the formation of CAA. While much is known about apoE receptor biology, the only known receptor for Clu, LRP2/Megalin, is very poorly expressed in the adult brain, suggesting other receptors are present but undiscovered. We have found that Plexin A4 (PLXNA4) is a novel receptor that regulates the levels of extracellular CLU in mice and in humans. PLXNA4 levels are significantly decreased in mouse models of AD as well as human AD brain tissue compared to controls. The objective of this proposal is to define how CLU regulates Aβ metabolism and deposition in brain parenchyma and cerebrovasculature. Using a combination of cell culture, biochemistry, mouse genetics, pharmacology, and pathologically defined human tissue, we will determine how the CLU and PLXNA4 affect AD by studying functional endpoints such as histopathology, vascular dysfunction, neuritic dystrophy, electrophysiology, and behavior. Deciphering this pathway could lead to new therapeutic targets not only for AD, but also for stroke and breast cancer, given the emerging role of CLU in those respective fields.
描述(由申请人提供):阿尔茨海默病(AD)是痴呆症的最常见病因,其特征在于淀粉样蛋白-β(Aβ)肽沉积形成的细胞外斑块和由过度磷酸化形式的tau蛋白组成的细胞内缠结。AD的另一种常见病理是脑淀粉样血管病(CAA),由脑血管壁中的Aβ沉积引起,导致血管功能障碍和出血。AD和CAA的最强遗传风险因素是载脂蛋白E(APOE)基因的ε4等位基因,但最近的多项全基因组关联研究证明,类似的载脂蛋白,胆固醇(CLU),也赋予AD的风险。CLU在CAA中的作用尚不清楚,但我们有强有力的证据表明CLU在CAA的形成中起着关键作用。虽然对apoE受体生物学了解很多,但Clu唯一已知的受体LRP 2/Megalin在成人大脑中表达非常差,这表明其他受体存在但未被发现。我们已经发现丛蛋白A4(PLXNA 4)是一种新型受体,其调节小鼠和人类细胞外CLU的水平。与对照相比,在AD小鼠模型以及人AD脑组织中PLXNA 4水平显著降低。本研究的目的是明确CLU如何调节Aβ在脑实质和脑血管中的代谢和沉积。使用细胞培养,生物化学,小鼠遗传学,药理学和病理学定义的人体组织的组合,我们将确定CLU和PLXNA 4如何影响AD通过研究功能终点,如组织病理学,血管功能障碍,神经炎性营养不良,电生理学和行为。破译这一途径不仅可以为AD,而且还可以为中风和乳腺癌提供新的治疗靶点,因为CLU在这些领域中的作用正在显现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John David Fryer其他文献
John David Fryer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John David Fryer', 18)}}的其他基金
Novel genetic modifiers of C9orf72 and Tau toxicity
C9orf72 和 Tau 毒性的新型遗传修饰剂
- 批准号:
10084641 - 财政年份:2019
- 资助金额:
$ 34.23万 - 项目类别:
Development and characterization of a novel Clusterin mouse model
新型 Clusterin 小鼠模型的开发和表征
- 批准号:
9065478 - 财政年份:2015
- 资助金额:
$ 34.23万 - 项目类别:
The role of Clusterin in cerebral amyloid angiopathy
Clusterin 在脑淀粉样血管病中的作用
- 批准号:
9765415 - 财政年份:2015
- 资助金额:
$ 34.23万 - 项目类别:
Understanding the Mechanisms of TDP-43 Function
了解 TDP-43 功能的机制
- 批准号:
8507420 - 财政年份:2013
- 资助金额:
$ 34.23万 - 项目类别:
Understanding the Mechanisms of TDP-43 Function
了解 TDP-43 功能的机制
- 批准号:
8613510 - 财政年份:2013
- 资助金额:
$ 34.23万 - 项目类别:
The role of capicua in spinocerebellar ataxia type 1
Capicua 在 1 型脊髓小脑共济失调中的作用
- 批准号:
7113397 - 财政年份:2006
- 资助金额:
$ 34.23万 - 项目类别:
The role of capicua in spinocerebellar ataxia type 1
Capicua 在 1 型脊髓小脑共济失调中的作用
- 批准号:
7243457 - 财政年份:2006
- 资助金额:
$ 34.23万 - 项目类别:
相似海外基金
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
- 批准号:
8757425 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
- 批准号:
8820188 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
- 批准号:
9040023 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
- 批准号:
8930156 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
- 批准号:
8897941 - 财政年份:2013
- 资助金额:
$ 34.23万 - 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
- 批准号:
8411069 - 财政年份:2013
- 资助金额:
$ 34.23万 - 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
- 批准号:
8713897 - 财政年份:2013
- 资助金额:
$ 34.23万 - 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
- 批准号:
7752282 - 财政年份:2009
- 资助金额:
$ 34.23万 - 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
- 批准号:
8090296 - 财政年份:2009
- 资助金额:
$ 34.23万 - 项目类别:
Development of therapeutics for dementia targeting Abeta clearance
开发针对 Abeta 清除的痴呆疗法
- 批准号:
20590697 - 财政年份:2008
- 资助金额:
$ 34.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)